Document is current
Any future updates will be listed below
-
Authors
Høgh, Julie
Arentoft, Nicoline
Schultz, Nicolai Aagaard
Bock, Ask
Møller, Dina Leth
Nordestgaard, Børge Grønne
Afzal, Shoaib
Aagaard, Niels Kristian
Fialla, Annette Dam
Holland-Fischer, Peter
Almdal, Thomas Peter
Hillingsø, Jens
Rasmussen, Allan
Vilsbøll, Tina
Nielsen, Susanne Dam
-
Funding
Funding for this research was provided by:
Rigshospitalet Research Foundation
Kirsten og Freddy Johansens Fond
Aase og Ejnar Danielsens Fond
Svend Andersen Fonden
Arvid Nilssons Fond
and the Research Foundation of University Hospital Odense and Copenhagen University Hospital – Rigshospitalet
- License Information
-
More Information
Article History
Received: 24 October 2025
Accepted: 17 April 2026
First Online: 27 April 2026
Declarations
:
: NA, NAS, AB, BGN, NKA, ADF, PHF, JH and AR have no conflicts of interest to declare. JH has received a research grant from the Research Council at Rigshospitalet. DLM reports lecture fees from Takeda. SA reports a travel grant from Abbott. TA holds stock in Novo Nordic. TV is currently employed by Novo Nordisk A/S, Denmark; the present work was done independently from this employment, and has served on scientific advisory panels, been part of speakers’ bureaus, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mass Medicine, Mundipharma, MSD/Merck, Novo Nordisk, Regor, Roche, Sanofi, Sun Pharmaceuticals and Zealand Pharma. SDN has received grants from the Research Council at Rigshospitalet, Sofus Carl Emil Friis and Wife Olga Doris Friis Scholarship, Svend Andersen Foundation, Kirsten and Freddy Johansen’s Foundation, Arvid Nilsson’s Foundation, Aase and Ejnar Danielsen’s Foundation, and the Research Foundation of University Hospital Odense and Copenhagen University Hospital – Rigshospitalet and honoraria from Gilead and MSD and has served on advisory boards for Gilead, MSD, and GSK.
